Market Overview

Viral Vector Manufacturing Market by Type, Disease, Application, End User - Global Forecast to 2023 - ResearchAndMarkets.com

Share:

The "Viral
Vector Manufacturing Market by Type, Disease, Application, End User -
Global Forecast to 2023"
report has been added to ResearchAndMarkets.com's
offering.

The viral vector manufacturing market is expected to reach USD 815.8
million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR
of 20.0%.

The growth of this market is expected to be driven by rising prevalence
of target diseases and disorders, the availability of funding for gene
therapy development, effectiveness of viral vectors in gene therapy
delivery, and ongoing research into viral vector-based gene & cell
therapies. On the other hand, the high cost of gene therapies and short
shelf-life of viral vectors are likely to restrain the growth of this
market to a certain extent.

By disease, the viral vector manufacturing market is segmented into
cancer, genetic disorders, infectious diseases, and other diseases.
During the forecast period, the genetic disorders segment is expected to
grow at the highest CAGR owing to the accelerated research activities on
various genetic disorders such as hemophilia A and B, sickle cell
anemia, and Huntington's disease.

Based on end user, the global viral vector manufacturing market is
segmented into pharmaceutical and biopharmaceutical companies and
research institutes. The pharmaceutical and biopharmaceutical companies
segment is expected to hold the largest share of the market in 2018. The
successful launch of viral vector gene therapies and a robust pipeline
of such therapies are the key factors contributing to the growth of the
pharmaceutical and biopharmaceutical companies segment during the
forecast period.

The major players in the global viral vector manufacturing market are
Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT
Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM
Diosynth Biotechnologies (US), and Spark Therapeutics (US).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Viral Vector Manufacturing Market, By Type

7 Viral Vector Manufacturing Market, By Disease

8 Viral Vector Manufacturing Market, By Application

9 Viral Vector Manufacturing Market, By End User

10 Viral Vector Manufacturing Market, By Region

11 Competitive Landscape

12 Company Profiles

  • Brammer Bio
  • Cell and Gene Therapy Catapult (CGT Catapult)
  • Cobra Biologics
  • Finvector Vision Therapies
  • Fujifilm Holdings Corporation
  • Kaneka Eurogentec
  • Lonza
  • Massbiologics
  • Merck KGaA
  • Novasep
  • Oxford Biomedica
  • Regenxbio
  • Spark Therapeutics
  • Uniqure

For more information about this report visit https://www.researchandmarkets.com/research/xqwsvb/viral_vector?w=4

View Comments and Join the Discussion!